Small molecule (oligosaccharide) for cystic fibrosis, chronic obstructive pulmonary disease, and chronic infections
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
157
NCT00970346
Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2009
Completion: Nov 30, 2009
NCT01465529
A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
Phase: Phase 1/2
Start: May 31, 2011
Completion: Nov 30, 2013
NCT01991028
A Study to Investigate Lung Deposition of Radiolabelled OligoG
Phase: Phase 2
Role: Collaborator
Start: Apr 30, 2014
Completion: Sep 30, 2014
NCT02157922
A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis
Start: Oct 31, 2014
Completion: Sep 30, 2017
NCT02453789
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
Start: Feb 28, 2015
Completion: Dec 31, 2017
NCT03822455
A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis
Start: May 16, 2019
Completion: Jul 10, 2021
NCT03698448
A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
Phase: Phase 2/3
Start: Sep 1, 2021
Completion: Nov 1, 2022
Loading map...